Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03717155
Other study ID # MS201944_0170
Secondary ID 2018-001529-24
Status Completed
Phase Phase 2
First received
Last updated
Start date October 30, 2018
Est. completion date May 27, 2021

Study information

Verified date April 2022
Source Merck KGaA, Darmstadt, Germany
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main purpose of the study was to investigate the clinical activity and safety of avelumab in combination with cetuximab plus gemcitabine and cisplatin in participants with treatment-naïve advanced squamous non-small-cell lung cancer (NSCLC).


Recruitment information / eligibility

Status Completed
Enrollment 43
Est. completion date May 27, 2021
Est. primary completion date September 30, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Histologically-confirmed Stage IV metastatic or recurrent (Stage IV) NSCLC of squamous histology - Availability of formalin-fixed paraffin-embedded (FFPE) block containing tumor tissue or a minimum of 15 (preferably 25) unstained tumor slides (cut within 1 week) suitable for Programmed death ligand 1 (PD-L1) expression and epidermal growth factor receptor (EGFR) expression/amplification assessments - At least 1 measurable lesion per response evaluation criteria in solid tumors (RECIST) v1.1 criteria - Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1 at study entry - Adequate hematological, hepatic and renal function - Estimated life expectancy of at least 3 months - Can give signed informed consent - Other protocol defined inclusion criteria could apply Exclusion Criteria: - Participants whose tumor disease harbors an activating EGFR mutation or ALK rearrangement. Participants with tumors of unknown EGFR or ALK status will require testing only in never smokers - All participants with brain metastases with protocol defined exceptions - Previous malignant disease (other than NSCLC) within the last 5 years (except adequately treated non-melanoma skin cancers, carcinoma in situ of skin, bladder, cervix, colon/rectum, breast, or prostate) unless a complete remission without further recurrence was achieved at least 2 years prior to study entry and the participant was deemed to have been cured with no additional therapy required or anticipated to be required - Active infection requiring systemic therapy - Known history of human immunodeficiency virus or known acquired immunodeficiency syndrome - Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening (positive HBV surface antigen or HCV ribonucleic acid (RNA) if anti-HCV antibody screening test positive) - Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent - Interstitial parenchymal lung disease - Pregnancy or lactation - Known alcohol or drug abuse as determined by the Investigator - History of uncontrolled intercurrent illness - Clinically significant (that is active) cardiovascular disease - Known history of inflammatory colitis, inflammatory bowel disease, pneumonitis, pulmonary fibrosis - Any psychiatric condition that would prohibit the understanding or rendering of informed consent or that would limit compliance with study requirements - Prior/Concomitant Therapy as described in protocol - Use of any investigational drug within 28 days before the start of study treatment - Other protocol defined exclusion criteria could apply

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Avelumab
Participants received avelumab intravenous infusions at a dose of 800 milligram (mg) on Day 1 and Day 8 of each 3-week cycle for the first 4 cycles. Thereafter, administered every 2 weeks in the Maintenance phase until disease progression or unacceptable toxicities.
Cetuximab
Participants received cetuximab intravenous infusions at a dose of 250 milligram per meter square (mg/m^2) body surface area on Day 1 and 500 mg/m^2 body surface area on Day 8 of first 4 cycles of concurrent chemotherapy. Thereafter, administered given at a dose of 500 mg/m^2 intravenous every 2 weeks in the Maintenance phase, until disease progression or unacceptable toxicities.
Gemcitabine
Participants received gemcitabine intravenous infusions at a dose of 1250 mg/m^2 body surface area on Day 1 and Day 8 in 3-week cycles up to a maximum of 4 cycles, until disease progression or unacceptable toxicities.
Cisplatin
Participants received cisplatin intravenous infusions at a dose of 75 mg/m^2 body surface area on Day 1 of 3-week cycles up to a maximum of 4 cycles, until disease progression or unacceptable toxicities.
Carboplatin
In case of cisplatin toxicities, participants were switched to carboplatin at a dose of target area under the serum concentration-time curve of 5 (AUC 5) on Day 1 for the remainder of cycles.

Locations

Country Name City State
Hungary Semmelweis Egyetem - Pulmonologiai Klinika Budapest
Hungary Debreceni Egyetem - Tudogyogyaszati Klinika Debrecen
Hungary Petz Aladar Megyei Oktato Korhaz - Pulmonologiai Osztaly Gyor
Hungary Markusovszky Egyetemi Oktatokorhaz Szombathely
Hungary Tudogyogyintezet Torokbalint - Onkopulmonologiai es Jarobeteg centrum Torokbalint
Hungary Zala Megyei Szent Rafael Korhaz Zalaegerszeg
Serbia Clinical Center "Bezanijska kosa" - Department of Oncology Belgrade
Serbia Clinical Center Kragujevac (no dept.) Belgrade
Serbia Institute for Pulmonary Diseases of Vojvodina Sremska Kamenica
Spain Complejo Hospitalario Universitario A Coruña - Servicio de Oncologia A Coruña
Spain Hospital Universitari Quiron Dexeus - Servicio de Oncologia Medica Barcelona
Spain Hospital Universitari Vall d'Hebron - Dept of Oncology Barcelona
Spain Hospital General Universitario Gregorio Marañon - Servicio de Oncologia Medica Madrid
Spain Hospital Universitario 12 de Octubre - Servicio de Oncologia Madrid
Spain Hospital Universitario HM Madrid Sanchinarro - Servicio de Oncologia Madrid
Spain Hospital Regional Universitario de Malaga Málaga
Spain Hospital Universitario Virgen del Rocio Sevilla
Spain Hospital Universitario Virgen Macarena - Servicio de Oncologia Sevilla
Spain Hospital Universitari i Politecnic La Fe - Servicio de Oncologia Medica Valencia
Spain Hospital Clinico Universitario Lozano Blesa - Dept of Oncology Zaragoza

Sponsors (1)

Lead Sponsor Collaborator
Merck KGaA, Darmstadt, Germany

Countries where clinical trial is conducted

Hungary,  Serbia,  Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Participants With Confirmed Best Objective Response (BOR) According to Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 Assessed by Investigator Confirmed BOR was defined as the percentage of participants who achieved confirmed complete responses (CR) or partial response (PR), according to RECIST version 1.1 assessed by the Investigator.CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. Stable disease (SD)= Neither sufficient increase to qualify for progression of disease (PD) nor sufficient shrinkage to qualify for PR. PD: At least a 20 % increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. Confirmed CR=as at least two determinations of CR at least 4 weeks apart with no PD. Confirmed PR=as at least 2 determinations of PR or better (PR followed by PR or PR followed by CR), at least 4 weeks apart (not qualifying for a CR) with no PD in between. Percentage of Participants with confirmed BOR were reported. Time from the first dose of study drug until occurrence of PD, death due to any cause (assessed up to 612 days)
Secondary Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Related Adverse Events (AEs), Treatment-Related Grade >=3 TEAEs and Immune-related Treatment Emergent AEs (irTEAEs) Adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease associated with the use of study drug, whether or not considered related to the study drug or worsening of pre-existing medical condition, whether or not related to study drug.Serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAE is defined as AEs starting or worsening after the first intake of the study drug. TEAEs include both Serious and non-serious TEAEs. irAEs included AEs that matches a preferred term on the list of pre-selected MedDRA terms. AEs with relationship to study treatment are reported as Treatment-related AEs. Treatment related AEs with grade 3 or more is also reported. Time from the first dose of study drug assessed up to (941 days)
Secondary Progression-Free Survival (PFS) Time Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Progression free survival (PFS) is defined as the time (in months) from first treatment day to the date of the first documentation of objective progression of disease (PD) according to RECIST version 1.1 assessed by Investigator, or death due to any cause, whichever occurs first. PD is defined as at least a 20 percent (%) increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. Time from the first dose of study drug until occurrence of PD, death due to any cause (assessed up to 737 days)
Secondary Duration of Response (DOR) DOR is defined for participants with confirmed complete response (CR) or partial response (PR), as the time from first documentation of confirmed response to the date of first documentation of progression of disease (PD) according to RECIST version 1.1 (assessed by Investigator) or death due to any cause or tumor assessment. Duration of objective response was assessed using Kaplan-Meier analysis. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the SLD of all lesions. PD: At least a 20 percent (%) increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. Time from the first dose of study drug until occurrence of PD, death due to any cause or last tumor assessment (assessed up to 612 days)
Secondary Immediate Observed Serum Concentration at End of Infusion (Ceoi) of Avelumab Ceoi is the serum concentration observed immediately at the end of infusion. This was taken directly from the observed Avelumab concentration-time data. Pre-dose, 2 hours after end of infusion on Day 1, 8, 22 and 29; Pre-dose, 30 minutes after the end of infusion on Day 43, 50, 64, 71; Pre-dose, 3 hours after end of infusion on Day 85, 99, 113, 127, 169, 253, and 337
Secondary Immediate Observed Serum Concentration at End of Infusion (Ceoi) of Cetuximab Ceoi is the serum concentration observed immediately at the end of infusion. This was taken directly from the observed cetuximab concentration-time data. Pre-dose, 2 hours after end of infusion on Day 1, 8, 22 and 29; Pre-dose, 30 minutes after the end of infusion on Day 43, 50, 64, 71; Pre-dose, 3 hours after end of infusion on Day 85, 99, 113, 127, 169, 253, and 337
Secondary Serum Trough Concentration Levels (Ctrough) of Avelumab Ctrough is the serum concentration observed immediately before next dosing. Pre-dose: Day 8, Day 22, Day 29, Day 43, Day 50, Day 64, Day 71, Day 85, Day 99, Day 113, Day 127, Day 169, Day 253 and Day 337
Secondary Serum Trough Concentration Levels (Ctrough) of Cetuximab Ctrough is the serum concentration observed immediately before next dosing. Pre-dose: Day 8, Day 22, Day 29, Day 43, Day 50, Day 64, Day 71, Day 85, Day 99, Day 113, Day 127, Day 169, Day 253 and Day 337
Secondary Overall Survival (OS) OS is defined as the time from the first treatment day to the date of death due to any cause. Overall survival was assessed using Kaplan-Meier analysis. Time from the first dose of study drug until occurrence of death due to any cause (assessed up to 941 days)
Secondary Number of Participants With Positive Anti-Drug Antibody (ADA) of Avelumab The detection of antibodies to avelumab was performed using a validated immunoassay method with tiered testing of screening, confirmatory and titration. Number of participants with positive anti-drug antibody (ADA) of avelumab were reported. Pre-dose up to 149 days
Secondary Number of Participants With Positive Anti-Drug Antibody (ADA) of Cetuximab The detection of antibodies to cetuximab was performed using a validated immunoassay method with tiered testing of screening, confirmatory and titration. Number of participants with positive anti-drug antibody (ADA) of cetuximab were reported. Pre-dose up to 149 days
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03542461 - Early Switch Maintenance vs Delayed Second-line Nivolumab in Advanced Stage Squamous Non-small Cell Lung Cancer (NSCLC) Patients (EDEN Trial) Phase 3
Not yet recruiting NCT04073537 - Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy in Subjects With Squamous Non-small Cell Lung Cancer Phase 3
Terminated NCT02204345 - A Study Evaluating RO5479599 in Combination With Carboplatin and Paclitaxel in Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) of Squamous Histology Phase 1/Phase 2
Terminated NCT01911325 - Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients Phase 1
Withdrawn NCT02924233 - Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer Phase 1/Phase 2
Withdrawn NCT03319316 - Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC) Phase 2
Completed NCT04552535 - A Study in the United States Using Electronic Medical Records (EMR) to Assess Effectiveness of Afatinib (Gilotrif) Following Pembrolizumab and Chemotherapy in the Treatment of Metastatic Squamous Cell Carcinoma of the Lung
Completed NCT01763788 - A Study of Necitumumab in the First-Line Treatment of Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) Phase 1/Phase 2
Not yet recruiting NCT05879484 - Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS Phase 1/Phase 2
Completed NCT02367794 - A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131] Phase 3
Recruiting NCT04149691 - Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies Phase 1
Recruiting NCT05243355 - Envafolimab Combined With Chemotherapy and Recombinant Human Endostatin in the First-line Treatment of Sq-NSCLC Phase 2
Completed NCT03366480 - A Study to Assess the Efficacy and Safety of ABTL0812 Phase 1/Phase 2
Not yet recruiting NCT04266730 - Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab Phase 1
Terminated NCT02109016 - A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations Phase 2
Completed NCT02106546 - Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer Phase 3
No longer available NCT02475382 - Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen